Efficacy and safety of degludec/liraglutide combination injection switching from basal insulin therapy with the DPP-4 inhibitor in Japanese type 2 diabetic patients

INTERVENTION: Switching from basal insulin and 20mg/day teneligliptin to insulin degludec/liraglutide combination injection over 24 weeks. Basal insulin is titrated with the aim of achieving a fasting self‐monitored blood glucose target of 80‐110 mg/dL. Switching from basal insulin and 20mg/day teneligliptin to basal insulin and 40mg/day teneligliptin over 24 weeks. Basal insulin is titrated with the aim of achieving a fasting self‐monitored blood glucose target of 80‐110 mg/dL. CONDITION: Type 2 diabets PRIMARY OUTCOME: Comparing the two groups change in HbA1c over the 24‐week treatment period SECONDARY OUTCOME: 1. Fasting plasma glucose; 2. Body weight; 3. creatinine; 4. eGFR; 5. Urine albumin/creatinine ratio; 6. Lipid profile; 7. Insulin dose; 8. Frequency of hypoglycemia; 9. Other adverse event INCLUSION CRITERIA: